

AASI for Psoriasis

All Classes

(Updated 08/28/2024)

AME Assisted Special Issuance (AASI) is a process that provides AMEs the ability to re-issue an airman medical certificate under the provisions of an Authorization for Special Issuance of a Medical Certificate (Authorization) to an applicant who has a medical condition that is disqualifying under Title 14 of the Code of Federal Regulations (14 CFR) part 67.

An FAA physician provides the initial certification decision and grants the Authorization in accordance with 14 CFR § 67.401. The Authorization letter is accompanied by attachments that specify the information that treating physician(s) must provide for the re-issuance determination. If this is first-time application for an AASI for the above disease/condition, and the applicant has all the requisite medical information necessary for a determination, the AME must defer and submit all of the documentation to the AMCD or RFS for the initial determination.

AMEs may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following:

1. An Authorization granted by the FAA; and
2. **A current, detailed Clinical Progress Note** generated from a clinic visit with the **treating Rheumatologist or Dermatologist no more than 90 days before** the AME exam. It must include:
 - A detailed interim summary;
 - Current medications, dosage, and side effects (if any);
 - Physical exam findings;
 - Results of all testing performed;
 - Diagnosis;
 - Assessment and plan (prognosis); and
 - Follow-up.
3. It must **specifically describe** if co-morbid conditions are present, they are appropriately managed, and that the individual was counseled regarding guideline-directed screening for co-morbid conditions.

AME must defer and describe in Block 60 what item(s) caused the deferral if the treating physician evaluation or AME exam identifies any of the following:

- **Any other disqualifying medical conditions** or therapy not previously reported;
- **Development of symptoms or medication side effects incompatible with aviation safety; or**
- **Guideline directed screening** for co-morbid conditions are not addressed.